Pelegrin M - Search Results

1

Monoclonal antibody-based genetic immunotherapy.

Pelegrin M, Gros L, Dreja H, Piechaczyk M. Pelegrin M, et al. Curr Gene Ther. 2004 Sep;4(3):347-56. doi: 10.2174/1566523043346246. Curr Gene Ther. 2004. PMID: 15384948 Review.

2

In vitro and in vivo secretion of cloned antibodies by genetically modified myogenic cells.

Noël D, Pelegrin M, Marin M, Biard-Piechaczyk M, Ourlin JC, Mani JC, Piechaczyk M. Noël D, et al. Among authors: pelegrin m. Hum Gene Ther. 1997 Jul 1;8(10):1219-29. doi: 10.1089/hum.1997.8.10-1219. Hum Gene Ther. 1997. PMID: 9215739

3

Systemic long-term delivery of antibodies in immunocompetent animals using cellulose sulphate capsules containing antibody-producing cells.

Pelegrin M, Marin M, Noël D, Del Rio M, Saller R, Stange J, Mitzner S, Günzburg WH, Piechaczyk M. Pelegrin M, et al. Gene Ther. 1998 Jun;5(6):828-34. doi: 10.1038/sj.gt.3300632. Gene Ther. 1998. PMID: 9747463

4

Genetically engineered antibodies in gene transfer and gene therapy.

Pelegrin M, Marin M, Noël D, Piechaczyk M. Pelegrin M, et al. Hum Gene Ther. 1998 Oct 10;9(15):2165-75. doi: 10.1089/hum.1998.9.15-2165. Hum Gene Ther. 1998. PMID: 9794201 Review.

5

Development of cellulose sulfate-based polyelectrolyte complex microcapsules for medical applications.

Dautzenberg H, Schuldt U, Grasnick G, Karle P, Müller P, Löhr M, Pelegrin M, Piechaczyk M, Rombs KV, Günzburg WH, Salmons B, Saller RM. Dautzenberg H, et al. Among authors: pelegrin m. Ann N Y Acad Sci. 1999 Jun 18;875:46-63. doi: 10.1111/j.1749-6632.1999.tb08493.x. Ann N Y Acad Sci. 1999. PMID: 10415557

6

Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type 2 diabetes.

Devedjian JC, George M, Casellas A, Pujol A, Visa J, Pelegrín M, Gros L, Bosch F. Devedjian JC, et al. Among authors: pelegrin m. J Clin Invest. 2000 Mar;105(6):731-40. doi: 10.1172/JCI5656. J Clin Invest. 2000. PMID: 10727441 Free PMC article.

7

Immunotherapy of a viral disease by in vivo production of therapeutic monoclonal antibodies.

Pelegrin M, Marin M, Oates A, Noël D, Saller R, Salmons B, Piechaczyk M. Pelegrin M, et al. Hum Gene Ther. 2000 Jul 1;11(10):1407-15. doi: 10.1089/10430340050057486. Hum Gene Ther. 2000. PMID: 10910138

8

Efficient cell infection by Moloney murine leukemia virus-derived particles requires minimal amounts of envelope glycoprotein.

Bachrach E, Marin M, Pelegrin M, Karavanas G, Piechaczyk M. Bachrach E, et al. Among authors: pelegrin m. J Virol. 2000 Sep;74(18):8480-6. doi: 10.1128/jvi.74.18.8480-8486.2000. J Virol. 2000. PMID: 10954548 Free PMC article.

9

Sustained systemic delivery of monoclonal antibodies by genetically modified skin fibroblasts.

Noël D, Pelegrin M, Brockly F, Lund AH, Piechaczyk M. Noël D, et al. Among authors: pelegrin m. J Invest Dermatol. 2000 Oct;115(4):740-5. doi: 10.1046/j.1523-1747.2000.00106.x. J Invest Dermatol. 2000. PMID: 10998153 Free article.

10

Skin as a potential organ for ectopic monoclonal antibody production.

Noël D, Dazard JE, Pelegrin M, Jacquet C, Piechaczyk M. Noël D, et al. Among authors: pelegrin m. J Invest Dermatol. 2002 Feb;118(2):288-94. doi: 10.1046/j.0022-202x.2001.01625.x. J Invest Dermatol. 2002. PMID: 11841546 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

46 results

Search Page

Filters